# Study of the AL3810 in the Treatment of Advanced Solid Tumor

> **NCT03117101** · PHASE1 · COMPLETED · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Lucitanib

## Key facts

- **NCT ID:** NCT03117101
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117101, "Study of the AL3810 in the Treatment of Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03117101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*